Ras-driven tumorigenesis is assumed to depend on Raf for ERK activation and proliferation; yet, an in vivo requirement for Raf as MEK/ERK activator in this setting has not been demonstrated to date. Here, we show that epidermis-restricted B-Raf ablation restrains the onset and stops the progression of established Ras-driven tumors by limiting MEK/ERK activation and proliferation. Concomitant elimination of B-Raf and Raf-1 enforces the abrupt regression of established tumors owing to the decrease in ERK activation and proliferation caused by B-Raf ablation combined with the ERK-independent increase in Rho-dependent kinase (Rok) signaling and differentiation triggered by Raf-1 inactivation. Thus, B-Raf and Raf-1 have non-redundant functions in Ras-driven tumorigenesis. Of note, Raf kinase inhibitors achieve impressive results in melanomas harboring oncogenic BRAF, but are ineffective against Ras-driven tumors; moreover, therapy-related skin tumors driven by a paradox ERK activation as well as primary and acquired resistance have been reported. Our results suggest that therapies targeting both Raf kinase-dependent and -independent pathways may be effective against a broader range of malignancies and reduce the risks of adverse effects and/or resistance.
INTRODUCTION
The epidermis constantly turns over to preserve its function as a barrier between the body and the environment. Changes in this self-renewal process, such as altered keratinocyte proliferation/ differentiation, can induce skin barrier defects or lead to tumor formation. Squamous cell carcinoma (SCC), a prevalent human skin cancer, is an example of a condition caused by an imbalance between keratinocyte proliferation, differentiation and apoptosis. Activation of the small GTPase Ras is observed in the majority of human SCC and is considered a pivotal event in its development. 1, 2 In animal models, activation of Ras by the transgenic expression of Ras mutant or by the expression of Ras-activating guanine nucleotide exchange factors in the basal layer of mouse epidermis induces proliferation, promotes survival and inhibits differentiation. [2] [3] [4] [5] Ras activation stimulates multiple effector molecules, several of which have been implicated in distinct aspects of skin tumorigenesis by gain-and loss-of-function experiments in the mouse. They include the phosphoinositide-3-kinase/Akt and the Tiam-1/Rac1 pathway, implicated in both proliferation [6] [7] [8] and survival, 5, 8, 9 and the Ral-GDS pathway, which protects the cells from apoptosis. 10 Undoubtedly however, the Ras-effector branch that is most directly connected with proliferation is the Raf/MEK/ERK pathway, 1,2 a three-tiered kinase cascade in which each tier is represented by more than one enzyme. In mammals, there are three Raf isoforms (A-Raf, B-Raf and Raf-1, also known as C-Raf), all of which bind to Ras and phosphorylate MEK; two MEK isoforms, both of which are phosphorylated by Raf and have a single common target, ERK; and two ERK isoforms, for which more than 100 substrates have been described. In mouse models, epidermisrestricted, inducible activation of Raf or MEK causes cutaneous hyperplasia and reduced differentiation. 2 While the ablation of B-Raf, 11 Raf-1, 12 MEK1, MEK2, 13 ERK1 or ERK2 14 does not impair epidermal homeostasis, simultaneous MEK1/MEK2 ablation results in hypoplasia and perinatal death, 13 and compound ERK1/ERK2 ablation inhibits keratinocyte division; 14 in addition, reducing the expression of MEK impairs Ras-induced epidermic hyperplasia, 15 and MEK1 or ERK1 ablation decreases chemical carcinogenesis. 16, 17 More recently, we have shown that one of the Raf kinases, Raf-1, is essential for both development and maintenance of Ras-driven tumors in vivo.
18 Surprisingly, Raf-1 was not required for the activation of the ERK pathway, but for the inhibition of the Rho-dependent kinase Rok-a, which drives keratinocyte differentiation. 1, 18 Consistent with this crucial role, RAF1 is overexpressed in human SCC. 19 Within the Raf/MEK/ERK pathway, BRAF is the only member frequently found mutated in human tumors, particularly in melanoma. The most common mutation, V600E, activates the kinase, resulting in sustained MEK/ERK signaling; less frequently, BRAF mutations reduce catalytic activity, but induce the formation of BRAF/RAF1 heterodimers, in which BRAF stimulates wild-type RAF1 in trans (reviewed in Wimmer and Baccarini 20 and Niault and Baccarini 21 ). Recently, selective BRAFV600E inhibitors have shown exceptional response rates in metastatic melanoma trials, a major breakthrough in the therapy of this incurable disease. 22, 23 The side effects are mild, but they include the rapid appearance of keratoacanthomas and SCC in situ. 20, 24, 25 The molecular mechanisms underlying this phenomenon are unknown, but it has been postulated that they may be connected to the ability of the inhibitors to promote the formation of BRAF/RAF1 dimers and activate the ERK pathway in wild-type cells and in cells expressing Ras mutations. [26] [27] [28] Together, the results above confirm the role of Raf and of the ERK pathway in promoting proliferation and inhibiting differentiation in the epidermis.
Against this background, we have generated an epidermisrestricted B-Raf knockout (KO) (K5Cre;b-raf flox/flox mice; hereafter referred to as D/Dep) as well as mouse strains allowing tamoxifen (TX)-inducible, epidermis-restricted ablation 29 of B-Raf, alone or in combination with Raf-1. We have used these strains to investigate the role of Raf in Ras-driven epidermis tumorigenesis, using either the DMBA/TPA chemical carcinogenesis protocol 30 or a genetic model in which a membrane-tethered form of the Ras activator SOS (Son Of Sevenless) expressed in basal keratinocytes 5 results in the constitutive activation of endogenous Ras, observed more frequently than Ras mutations in human SCC. 31 
RESULTS

B-Raf ablation restrains Ras-dependent tumor formation
To investigate the role of B-Raf in Ras-dependent tumor formation, we combined epidermis-restricted B-Raf ablation (D/Dep, deleted in epidermis) with the DMBA/TPA chemical carcinogenesis protocol, largely driven by an activating mutation in codon 61 of the ras gene 32 (Figure 1a ), or with a genetic model in which the expression of a membrane-tethered form of the Ras-guanine nucleotide exchange factor SOS expressed under the control of the K5 promoter (K5-SOS-F) 5 drives the activation of endogenous, wild-type Ras (Figure 1e ), mimicking the situation observed in the majority of human SCCs. 31 Application of DMBA/TPA to the dorsal skin of wild-type (f/f) mice induced visible tumors within 6 weeks, with a 50% penetrance by week 13 (Figures 1a and b) . Four out of four wild-type and B-Raf D/Dep tumors contained the Q61L HRas mutation (data not shown), indicating that B-Raf ablation did not prevent the keratinocytes from acquiring this mutation. All of the K5-SOS-F þ ;f/f mice developed visible, fastgrowing tumors, mostly papillomas, predominantly on the tail, ears and at sites subjected to scratching and biting 5 by the sixth week of life (Figure 1f Chemically-induced f/f and D/Dep tumors examined at week 20 were papillomas of different sizes but similar in structure, projecting above the surrounding tissue (Figures 1a and c) . Similarly, the analysis of size-matched K5-SOS-F þ ;f/f and K5-SOS-F þ ;D/Dep did not reveal any structural differences between genotypes (Figure 1g ). In the latter case, as D/Dep tumors never reached the size of f/f tumors, only small and medium-sized tumors, all papillomas, were analyzed. Because of their slow growth rate, the D/Dep samples were taken from animals much older than the f/f tumors. Although the numbers of proliferating cells in the tumors varied, chemically-induced and K5-SOS-F þ D/Dep tumors contained about 50% less BrdU þ cells than f/f tumors (Figures 1c, d, g and h) . f/f tumors expressed the differentiation marker K10 only in 24-28% of the cells confined to the uppermost layer of the epidermis (Grade 3-4 according to Broder's classification). In contrast, D/Dep papillomas contained around between 72 and 79% K10 þ cells (Grade 1-2; Figures 1c, d, g and h) .
Apoptotic cells were rarely found in f/f and D/Dep tumors ( Supplementary Figures 1a and b) . Thus, B-Raf ablation reduced proliferation and increased differentiation in both chemically induced and SOS-F-driven tumors. Consistent with this, SOS-F expression failed to induce proliferation and to prevent differentiation in B-Raf-deficient epidermis (Figures 2a-d) .
Together, these data indicate a requirement for B-Raf in the development of Ras-driven epidermal tumors. B-Raf is necessary for the growth of established K5-SOS-F-induced tumors Next, we investigated whether B-Raf is required for the maintenance of Ras-driven tumors. To do this, we used the transgenic model of SOS-F-induced tumors, which, thanks to the synchronous, easily monitorable and quantifiable development of the lesions, allows a much more precise assessment of the impact of B-Raf ablation than the more heterogenous chemical carcinogenesis model. We generated K5-SOS-F;K5-Cre-ER(T);b-raf f/f mice, in which the Cre recombinase is expressed from the K5 promoter as a fusion protein that can be activated by 4-hydroxytamoxifen binding. 29 To induce b-raf ablation K5-SOS-F;K5-Cre-ER(T);b-raf f/f and their K5-SOS-F;b-raf f/f littermates bearing tumors of 0.3-0.7 cm in diameter were injected with TX (1 mg per day intraperitoneally, 5 consecutive injections). f/f tumors progressed by doubling or tripling in size in the 2 weeks after the last TX injection, whereas the lesions from conditional KO mice (D/DepTX) stopped growing but never resolved completely (Figures 3a and  b) . The f/f allele was efficiently converted to D/D in these lesions, indicating that their persistence was not due to incomplete recombination (Supplementary Figure 2) . Of note, TX injection does not slow down tumor progression in K5-SOS-F;K5-Cre-ER(T) mice. 33 The standstill of the D/DepTX tumors was accompanied by a 50% decrease in the number of proliferating cells, all restricted to the basal level ( Figure 3c) ; importantly, however, the number of proliferating cells did not decrease further with time and remained constantly above the 3-5% BrdU þ cells detected in the normal epidermis. The number of differentiating cells increased and suprabasal K10 staining was restored (Figure 3d ). The compaction Figure 1c) . Together, the data indicate that the progression of B-Raf KO tumors is brought to a halt by a decrease in proliferation accompanied by a gradual increase in differentiation of the tumor cells (Figures 3c and d) .
Roles of Raf in Ras-driven tumorigenesis F Kern et al B-Raf deficiency alters the proliferation and increases the differentiation of K5-SOS-F þ keratinocytes in vitro To determine the relationship between decreased proliferation and increased differentiation in B-Raf-deficient tumors, we isolated primary keratinocytes and monitored their ability to proliferate and differentiate in vitro. The consequences of B-Raf ablation on keratinocyte proliferation were determined by assessing the percentage of cells incorporating BrdU, to avoid taking into account the reduction of cell numbers owing to increased differentiation or decreased survival. In vitro, K5-SOS-F þ keratinocytes proliferate very poorly (Figure 3e ), 18 in agreement with the many observations showing that both cultured cells and premalignant tumors react to the hyperactivation of the Ras/Raf/ MEK/ERK pathway with growth arrest. 34 Figures 3f and g ). Under these conditions, K5-SOS-F expression maintained proliferation and prevented the differentiation of f/f keratinocytes; B-Raf ablation reduced SOS-F-driven proliferation and partially restored differentiation (Figures 3f and g ). These results are entirely consistent with those obtained in vivo (Figures 1-3) .
B-Raf ablation correlates with reduced ERK activation in vitro and in vivo To gain insight into the mechanisms underlying the D/Dep phenotype, we monitored the activation of the classical Raf effectors MEK/ERK. MEK/ERK phosphorylation was reduced in B-Raf-deficient keratinocytes deprived of growth factors for 12 h; the pathway still reacted to growth factor stimulation and was induced by K5-SOS-F expression, but less efficiently than in f/f cells (Figure 4a and Supplementary Figure 3a) . ERK phosphorylation was also reduced in B-Raf-deficient keratinocytes during CaCl 2 -induced differentiation (Figure 4b and Supplementary  Figure 3a) . Activation of the Rok pathway, which plays a crucial role in keratinocyte differentiation, 18, 35, 36 was measured by the phosphorylation of the downstream target cofilin. SOS-F inhibited cofilin phosphorylation; in agreement with our previous data showing that pharmacological MEK/ERK inhibition induces cofilin phosphorylation in wild-type and K5-SOS-F þ keratinocytes, 18 reduced ERK phosphorylation in B-Raf-deficient cells correlated with a partial rescue of cofilin phosphorylation (Figure 4b and Supplementary Figure 3b) . In vivo, B-Raf ablation completely prevented ERK phosphorylation in K5-SOS-F þ epidermis at the time of tumor onset ( Figure 4c ) and strongly reduced it in regressing established tumors (Figure 4d, upper panel) . Consistent with the increased differentiation observed in the B-Raf-deficient tumors (Figure 3d ), cofilin phosphorylation was also increased (Figures 4c and d, lower panel) ; however, close examination revealed that the staining was mostly confined to the suprabasal layers, while basal keratinocytes were typically negative (Figure 4d, lower panel) .
Concomitant ablation of B-Raf and Raf-1 causes the abrupt regression of Ras-driven tumors The signaling alterations described above are clearly distinct from those caused by Raf-1 ablation, in which ERK activation was maintained but cofilin phosphorylation was induced in cells of the basal layer. 18 To investigate the genetic interaction between B-Rafand Raf-1-dependent pathways in Ras-driven epidermal tumors, we generated K5-SOS-F-expressing conditional double-KO mice (D/Dep2TX) and induced the deletion of both alleles in tumors of (Figures 5a and b) , much faster than B-Raf-KO (Figure 3) or Raf-1-KO 18 tumors. The regressing tumors showed a profound decrease in proliferation and a strong increase in differentiation, but again no increase in apoptotic cells (Figure 5c and Supplementary Figure 1c) . Mechanistically, ERK phosphorylation was strongly decreased, while cofilin phosphorylation was increased in the regressing tumors, including in the basal layer (Figure 5d ). Consistent with this, phosphorylation of STAT3 and Figure 4) . In line with the in vivo phenotype, double-KO keratinocytes proliferated poorly in high-CaCl 2 cultures (Figure 5e ) and differentiated even more efficiently than wild-type cells despite the presence of SOS-F (Figure 5f ). Continuously growing double-KO cells showed both the decrease in pERK typical of the B-Rafdeficient keratinocytes and the increase in pCofilin characteristic of Raf-1-deficient cells (Figure 5g and Supplementary Figures 5a  and b) . Double-KO cells simply combined the effects on ERK and Cofilin phosphorylation observed in the single-KO cells, implying distinct essential functions of B-Raf and Raf-1 in Ras-driven ERK activation and cross-talk with the Rho pathway; in addition, SOS-Fdriven ERK activation was most pronouncedly reduced in double-KO cells, although the difference between B-Raf-deficient and double-KO cells was not significant.
DISCUSSION
Our data provide evidence that B-Raf ablation in keratinocytes strongly reduces carcinogenesis driven by mutational activation of Ras (DMBA/TPA model) or by the constitutive activation of endogenous Ras (K5-SOS-F model). Thus, B-Raf joins Raf-1 18 and Rac1 6 in the list of Ras effectors required in a cell-autonomous manner for this process. These data represent the first in vivo demonstration that B-Raf is essential for Ras-driven tumorigenesis; indeed, B-Raf is dispensable for the development of non-small-cell lung carcinoma downstream of oncogenic K-Ras. 38, 39 Raf-1, in contrast, is absolutely required for the development of these tumors, but an effect of its ablation on Ras-driven ERK activation could not be demonstrated. 38, 39 In the epidermis, B-Raf ablation stops the growth of established tumors and causes their slow regression, indicating a requirement that extends to tumor progression. Among the Ras effectors, a requirement for tumor maintenance had so far been demonstrated only for Raf-1. 18 The two Raf kinases, however, act on distinct signaling pathways and processes downstream of Ras in the epidermis. Consistent with the observation that inducible activation of Raf or MEK in the epidermis induces cutaneous hyperplasia and reduces differentiation, 40 B-Raf is necessary for full-fledged MEK/ERK activation and supports cell proliferation at the expense of differentiation in K5-SOS-F þ tumors in vivo and in CaCl 2 -treated keratinocytes in vitro (Figures 1-3) . Residual MEK/ ERK activation in B-Raf-ablated cells, mediated either by the other Figure 6 . Non-redundant roles of B-Raf and Raf-1 in Ras-driven epidermal tumorigenesis-a working model. Ras activation induces Raf-dependent MEK/ERK stimulation, which results in cell proliferation; and promotes the physical interaction of Raf-1 with Rok-a, which dims Rok-a activity and inhibits keratinocyte differentiation (top panel). Ablation of B-Raf decreases ERK activation and proliferation, but the presence of Raf-1 continues to inhibit differentiation; the net result is decreased tumor growth (middle left panel). Ablation of Raf-1, on the other hand, does not impact ERK activation but causes Rok-a hyperactivation, enforcing keratinocyte differentiation and the active regression of tumors. In compound B-Raf/Raf-1-KO tumors, the combination of these effects causes abrupt tumor regression.
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Raf kinases or by alternative kinases such as PAK, 6 is not sufficient to induce growth arrest in premalignant, K5-SOS-F þ keratinocytes (Figure 3e ) and to sustain tumorigenesis (Figures 3a and b) . These data are in agreement with previous results showing that MEK gene dosage, and therefore strength of ERK activation, is ratelimiting for the hyperplastic response of mouse epidermis to activated Ras. 15 In contrast to B-Raf, Raf-1 is dispensable for ERK activation (Figure 5g ) and its ablation does not relieve the growth arrest induced by K5-SOS-F þ in cultured premalignant keratinocytes. 18 Instead, Raf-1 works as an endogenous Rok-a inhibitor to counteract differentiation in keratinocyte cultures and in vivo, where Raf-1 ablation induces the synchronous activation of Rok-a (measured as the phosphorylation of the downstream target Cofilin) in all layers of the epidermis, enforces differentiation and causes complete tumor regression. 18 Together, these data suggest that B-Raf alters the balance between proliferation and differentiation primarily by acting as a MEK/ERK activator and thereby sustaining SOS-F-induced proliferation in tumors; Raf-1, in contrast, acts primarily as a Rok-a inhibitor preventing differentiation and thereby allowing sustained proliferation.
The effects of the two Raf proteins are independent from one another, and double-KO keratinocytes recapitulate the biochemical alterations observed in the single KOs without demonstrable significant synergism at the level of the ERK or Cofilin pathway; alterations in both pathways, however, engender the synergistic regression of SOS-F-induced tumors upon concomitant ablation of B-Raf and Raf-1 ( Figure 6 ). Interestingly, the Raf proteins, alone or in combination, do not play an essential role in apoptosis (Supplementary Figure 1) . 18 This function appears to be effected in vivo by other Ras downstream targets such as RalGDS or phosphoinositide-3 kinase. 9, 10 The data above indicate that the concomitant disruption of both Raf-1 and B-Raf-dependent signaling pathways would be an optimal strategy for the therapy of Ras-dependent skin tumors, and possibly of other malignancies. In melanoma expressing activating B-Raf mutations, for instance, RAF inhibitors achieve spectacular clinical success, but only in doses causing X80% inhibition of the ERK pathway; 23 such levels of ERK inhibition, however, might have considerable side effects, as suggested by the lethal outcome of compound MEK1/2 or ERK1/2 ablation in adult mice, while the compound knockout of B-Raf and Raf-1 is well tolerated. 39 In addition, both primary insensitivity and acquired resistance to RAF inhibitors have been reported 41, 42 and in a subset of melanoma cells they correlate with elevated RAF1 protein levels. 43 Finally, B-Raf mutations that do not increase intrinsic kinase activity appear to signal through Raf-1 downstream of Ras in melanoma, 44 and about 30% metastatic melanoma patients benefiting from the treatment with currently available Raf inhibitors develop SCCs, 22, 23 tentatively attributed to the activation of the MEK/ERK pathway by drug-induced B-Raf/Raf-1 dimers. 20, [26] [27] [28] Taken together, the evidence that Raf-1 operates via direct protein-protein interaction with B-Raf, Rok-a or other targets in the epidermis, 18, 27 and possibly in other tissues, 38, 39 makes therapeutic strategies silencing Raf-1 and B-Raf expression or small-molecule inhibitors disrupting Raf dimerization and/or its association with other proteins (Raf-/Rok-a) appear preferable to those aimed at blocking enzymatic activity; by simultaneously targeting both kinase-dependent and -independent Raf signaling pathways, these therapies might reduce the risk of adverse effects as well as the incidence of primary or acquired resistance. ; c-raf-1 f/f (doubleD/ DepTX), plus or minus the K5-SOS-F þ transgenes were bred by crossing the appropriate genotypes. All strains were maintained on a 129Sv background. Genotyping was performed as described previously. 11, 18 All animal experiments were performed in accordance with a protocol authorized by the Austrian Ministry of Science and Communications, following the approval by the national Ethical Committee for Animal Experimentation.
MATERIALS AND METHODS
Sequencing
To examine the induction of HRAS mutations at codon 61 by treatment with DMBA, DNA was extracted from B-Raf f/f and D/Dep SCC specimens with a tumor cell proportion of at least 70% using the QIAamp DNA Mini Kit for FFPE Tissue (Quiagen, Hilden, Germany). Mouse HRAS exon 3 was PCR-amplified and sequenced as previously described. 28 Ras activation assay Ras-GTP-pulldown assay was performed on primary keratinocytes lysates according to the manufacturer 0 s recommendation (Cytoskeleton Inc., Denver, CO, USA).
Laser capture microdissection
To confirm the efficient conversion of the b-raf f/f to D/D alleles in TXinjected animals, a Leica LMD6500-Laser Capture Microdissection/Imaging Unit (Leica Microsystems, Wetzlar, Germany) was used to dissect 50 000-100 000 mm 2 from rehydrated 7-mm-thick tumor sections from PEN-MembranSlides (Leica Microsystems). The collected tissue was digested and genotyped using the standard PCR protocol with extended cycle numbers.
Measurement of tumor volume
The length and width of each tumors were measured in vivo using a vernier scale caliper. Tumor volume was estimated using the formula (width 2 Â length)/2 for the ellipsoid, for the DMBA/TPA model, or area of the base (that is, the widest part of the tumor) Â length)/3 for the cone, for the K5-SOS-F þ tumors.
Statistical analysis
All values plotted represent the mean (±s.d.) of at least three independent experiments. P values were calculated with the two-tailed Student's t-test. A P value o0.05 is considered statistically significant.
Histological analysis
Hematoxylin/eosin staining and immunohistochemistry were performed on 3-mm-thick sections of 4% paraformaldehyde-fixed and paraffinembedded tissues. 18 Staining with the following antibodies was performed: a-BrdU (1:100; Abcam, Cambridge, UK), a-c-myc (1:250; Millipore, Billerica, MA, USA), a-K5 and a-K10 (1:500; BabCo/Covance, Princeton, NJ, USA), a-pCofilin (Ser3, 1:50; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), a-pERK (Thr202/Tyr204, 1:50) and a-pSTAT3 (Tyr705, 1:100; both Cell Signaling Technology, Boston, MA, USA). For detection, we used the DAKO EnVision peroxidase system, followed by incubation with 0.01% diaminobenzidine (Sigma-Aldrich, St Louis, MO, USA), in conjunction with avidin-biotinylated enzyme complex (Vector Laboratories, Burlingame, CA, USA) for biotinylated antibodies. Sections were counterstained with hematoxylin. BrdU incorporation was determined in mice injected with BrdU (12.5 mg/g body weight) 1 h prior to tissue isolation.
Keratinocyte isolation and culture
Primary-mouse keratinocytes were isolated from 18-to 21-day-old mice as previously described. 18 Differentiation was induced by transferring the cells into starvation medium (containing only 2% chelated FCS and no growth factors) and treating them with 1.2 mM CaCl 2 for different time periods. Differentiated cells were detected by immunofluorescence using a-Involucrin antibodies (1:500; BabCo/Covance) followed by a secondary FITC antibody (a-rabbit Alexa 448 nm, 1:1500; Molecular Probes/Life Technologies, Carlsbad, CA, USA). Microscopical analysis was performed with an Axiovert 200 (Carl Zeiss MicroImaging Inc., Oberkochen, Germany) equipped with an AxioCam. Images were acquired with the AxioVision Software (Carl Zeiss MicroImaging, Inc.) Proliferation was assessed by the In Roles of Raf in Ras-driven tumorigenesis F Kern et al
